By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

Avastin (bevacizumab) is a prescription drug used to treat certain types of cancer. Avastin is also available as a biosimilar drug. It’s prescribed for adults ages 18 years and older.